Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Michael GnantFlorian FitzalGabriel RinnerthalerGuenther G StegerSigrun Greil-ResslerMarija BalicDietmar HeckRaimund JakeszJosef ThalerDaniel EgleDiether ManfredaVesna Bjelic-RadisicUrsula WiederChristian F SingerElisabeth Melbinger-ZeinitzerFerdinand HaslbauerPaul SeveldaHarald TraplViktor WetteKerstin WimmerSimon P GampenriederRupert BartschStephanie Kacerovsky-StroblChristoph SuppanChristine BrunnerChristine DeutschmannLidija SoelknerChristian FeslRichard Greilnull nullPublished in: The New England journal of medicine (2021)
In postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture. (Funded by AstraZeneca and the Austrian Breast and Colorectal Cancer Study Group; ABCSG-16/SALSA ClinicalTrials.gov number, NCT00295620.).